Lorundrostat
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Lorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure. In clinical trials as an add-on medication for people with uncontrolled hypertension, decreased renin and elevated aldosterone it significantly reduced blood pressure. Hyperkalemia occurred in some trial participants. In a meta-analysis analysing data from 3 randomized controlled trials over 3 months of clinical use, lorundrostat at 50-100mg/day was found to be effective in lowering blood pressure, with associated issues of mild increase in serum potassium levels and decline in the glomerular filtration rate
Lorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure. In clinical trials as an add-on medication for people with uncontrolled hypertension, decreased renin and elevated aldosterone it significantly reduced blood pressure. Hyperkalemia occurred in some trial participants. In a meta-analysis analysing data from 3 randomized controlled trials over 3 months of clinical use, lorundrostat at 50-100mg/day was found to be effective in lowering blood pressure, with associated issues of mild increase in serum potassium levels and decline in the glomerular filtration rate
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1365132263 under CC BY-SA 4.0; modifications have been made.